InMed Pharmaceuticals Inc. (INM): auditor change — InMed Pharmaceuticals' auditor KPMG resigns; Marcum appointed as successor

InMed Pharmaceuticals Inc.

KPMG resigned as independent auditor on Dec 8, 2022, declining to stand for reelection; no disagreements on accounting matters.
KPMG's FY2022 and FY2021 audit reports included a going-concern paragraph citing substantial doubt about InMed's ability to continue.
InMed had an unremediated material weakness in internal control over financial reporting as of June 30, 2022.
Audit Committee appointed Marcum LLP as new auditor on Dec 11, 2022, subject to standard client acceptance procedures.
No consultations with Marcum before engagement on accounting or audit matters.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

InMed Pharmaceuticals Inc. engaged Marcum LLP as its auditor.

Action: engagement
Auditor: Marcum LLP

Exact text from the filing

On December 11, 2022, the Audit Committee approved the engagement of Marcum LLP ("Marcum") to audit our consolidated financial statements for the fiscal year ending June 30, 2023, subject to Marcum's standard client acceptance procedures.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

KPMG LLP resigned as auditor of InMed Pharmaceuticals Inc..

Action: resignation
Auditor: KPMG LLP

Exact text from the filing

On December 8, 2022, KPMG LLP ("KPMG"), which had been serving as the independent registered public accounting firm of InMed Pharmaceuticals Inc. ("we," "us" or "our"), declined to stand for reelection and resigned as our independent registered public accounting firm, effective immediately.

View on SEC.gov

12 auditor changes filed in the last 30 days. Browse all auditor changes →

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-079246

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.